[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …
…, C Ficko, S Figueiredo, B Gaborit, R Gaci… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
[HTML][HTML] An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients …
…, J Courjon, S Leroy, J Mootien, R Gaci… - Clinical Microbiology …, 2021 - Elsevier
Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir,
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …
[HTML][HTML] ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19
…, N Fuentes, M Fukuda, G Argin, V Gaborieau, R Gaci… - Scientific data, 2022 - nature.com
The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)
COVID-19 dataset is one of the largest international databases of prospectively collected …
COVID-19 dataset is one of the largest international databases of prospectively collected …
[HTML][HTML] Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …
…, M Saccu, D Barraud, Z Cavalli, R Gaci… - …, 2023 - thelancet.com
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients
…, C FLATEAU, V DINOT, R GACI… - Journal of Medical …, 2021 - Wiley Online Library
Little is known on the association between clinical factors and coronavirus disease 2019 (COVID‐19)
more than 15 days after diagnosis. We conducted a multicentric prospective cohort …
more than 15 days after diagnosis. We conducted a multicentric prospective cohort …
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
…, C Fougerou, V Fraipont, B Gaborit, R Gaci… - The Lancet Infectious …, 2022 - thelancet.com
We reported the preliminary results of the DisCoVeRy trial regarding the efficacy and safety
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …
Francisella tularensis endocarditis: two case reports and a literature review
R Gaci, C Alauzet, C Selton-Suty, A Lozniewski… - Infectious …, 2017 - Taylor & Francis
We report the first two cases of infective endocarditis caused by Francisella tularensis in
Europe (two cases have previously been reported outside Europe). We suggest clinicians …
Europe (two cases have previously been reported outside Europe). We suggest clinicians …
Antiviral drugs in hospitalized patients with COVID-19-the DisCoVeRy trial
…, C Dubost, J Courjon, S Leroy, J Mootien, R Gaci… - MedRxiv, 2021 - medrxiv.org
Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine
efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective …
efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective …
[HTML][HTML] Comparison of SARS-CoV-2 variants of concern alpha (B. 1.1. 7) vs. beta (B. 1.351) in critically ill patients: A multicenter cohort study
…, C Goetz, S Gibot, P Dunand, M Conrad, R Gaci… - Frontiers in …, 2022 - frontiersin.org
Objectives The clinical outcomes of the Beta (B.1.351) variant of concern (VOC) of the SARS-CoV-2
virus remain poorly understood. In early 2021, northeastern France experienced an …
virus remain poorly understood. In early 2021, northeastern France experienced an …
Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
…, A Gagneux-Brunon, G Thiery, F Bénézit, R Gaci… - medRxiv, 2022 - medrxiv.org
Background The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating
its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen and…
its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen and…
